Companies · Co-founded · Multiple Exits

Ventures. Built, operated, exited.

The companies co-founded and operated across three decades. Exit detail captured row by row.

Companies co-founded.

Hillman Ventures

Founded 1995. Dallas. Private family office investing personal capital in FDA-regulated frontier biotech. Active.

Affinity Healthcare Systems Inc

2007 to 2010. Co-founder. FDA-regulated specialty healthcare services. Exited to Dynacq Healthcare (NASDAQ: DYII).

PPM Rehabilitation

2011 to 2016. Co-founder. Rehabilitation services platform. Exited to Next Health.

Advanced Total Management

2012 to 2017. Co-founder. Pharmaceutical wholesale distribution. Exited to Next Health logoNext Health (LinkedIn).

Infinity Toxicology LLC

2012 to 2020. Co-founder. CLIA Highly Complex toxicology laboratory. Exited to Critical Healthcare Ltd, UK.

Apothecary Shop Pharmacy

2007 to 2014. Co-founder. Specialty pharmacy services. Exited to Pharma Holdings U.S. logoPharma Holdings U.S.

Dallas Claims Assistance

1998 to 2005. Co-founder. Healthcare claims processing. Exited to The Alpha Group (TAG).

Current focus areas

Mesenchymal exosome biologics on the 351(a) BLA pathway. Targeted Osmotic Lysis for solid tumors with an academic medical foundation.

Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. References here describe investment focus and published scientific literature. They do not describe an available treatment. Targeted Osmotic Lysis is investigational. It is not approved by the FDA for any indication, it has not been shown to be safe or effective in humans, and it is not available as a treatment. No clinical trial of it is registered on ClinicalTrials.gov.